Darolutamide in Japanese patients with metastatic hormone‐sensitive prostate cancer: Phase 3 ARASENS subgroup analysis

Darolutamide in Japanese patients with metastatic hormone‐sensitive prostate cancer: Phase 3 ARASENS subgroup analysis

Abstract Background In the global ARASENS study (NCT02799602), darolutamide plus androgen‐deprivation therapy (ADT) and docetaxel significantly reduced risk of death by 32.5% versus placebo plus ADT and docetaxel (hazard ratio [HR] 0.68; 95% confidence interval [CI] 0.57–0.80; p < 0.0001), with a...

Full description

Saved in:
Bibliographic Details
Main Authors: Motohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, Hiroji Uemura, Atsushi Mizokami, Masashi Kato, Hisashi Matsushima, Takeo Kosaka, Motonobu Nakamura, Satoshi Fukasawa, Matthew R. Smith, Bertrand Tombal, Maha Hussain, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Haruka Kakiuchi, Masanao Akiyama, Rui Li, Iris Kuss, Heikki Joensuu, Hiroyoshi Suzuki
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Cancer Medicine
Subjects:
darolutamide
efficacy
Japanese
metastatic hormone‐sensitive prostate cancer
safety
Online Access:https://doi.org/10.1002/cam4.70029
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70029

Similar Items